Clinical trials
ER+ Breast Cancer clinical trials
Below are recruiting er+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 554 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06188520RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors in women
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
St Louis, MissouriAges 18 years+ - NCT05989347RecruitingPhase 1
Dapagliflozin with chemo for breast cancer
This trial tests whether adding the drug dapagliflozin (a pill that lowers blood sugar) to standard chemotherapy before breast cancer surgery can improve outcomes. It is for women with high insulin levels and a higher BMI who are about to start chemotherapy.
New Haven, ConnecticutAges 18 years+ - NCT05914961Recruiting
Tracking inflammation response in triple-negative breast cancer
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
TübingenAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT04677816RecruitingPhase 2
Vitamin D for a better response to chemotherapy
This study tests whether taking high-dose vitamin D before and during chemotherapy helps eliminate more cancer before surgery in people with triple-negative breast cancer who are low in vitamin D.
Winston-Salem, North CarolinaAges 18 years+ - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
San Francisco, CaliforniaAges 18 years+ - NCT03804944RecruitingPhase 2
Vaccine trial for hormone-positive breast cancer
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
Los Angeles, CaliforniaAges 18–90 - NCT02422641RecruitingPhase 2
High-dose methotrexate for breast cancer in the brain lining
This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.
Baltimore, MarylandAges 18 years+ - NCT04293796Recruiting
Skipping breast surgery after complete response
This trial looks at whether some people with breast cancer can safely avoid breast surgery after they respond completely to treatment before surgery. If you have no remaining cancer in the tissue and lymph node tests, this study checks whether the “watch-and-wait” approach is feasible and safe.
Saint PetersburgAges 18–70 - NCT06342037RecruitingPhase 2
New immunotherapy options for advanced triple-negative breast cancer
This trial tests two immunotherapy drugs (atezolizumab and tiragolumab) for people with advanced triple-negative breast cancer that has not responded to standard treatments. It aims to see if this combination can shrink or slow the cancer.
Amsterdam, North HollandAges 18 years+ - NCT06195709RecruitingPhase 3
Study of PET imaging and blood tests for ER+ HER2- metastatic breast cancer
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
BayonneAges 18 years+ - NCT03815890RecruitingPhase 2
Pre-surgery nivolumab for certain types of breast cancer
This trial tests whether giving nivolumab before surgery (neoadjuvant treatment) can improve outcomes for people with certain resectable breast cancers. It focuses on tumor types linked to immune activity (like triple-negative and specific lab markers).
AmsterdamAges 18 years+ - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT04278469Recruiting
Study for early breast cancer patients with low-risk genes
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
SeoulAges 19–80 - NCT06925984Recruiting
Targeted radiation for breast cancer that has spread and is growing a little
This trial tests whether giving focused, high-dose radiation to spots where the cancer is growing can help control the disease while you stay on your current hormone therapy and/or CDK4/6 inhibitor. It is for people with ER+/HER2- breast cancer that has spread to a few places and is slowly starting to progress.
BrusselsAges 18 years+ - NCT07546695Recruiting
Axillary lymph node surgery choices for HER2+ and triple-negative breast cancer
This study examines the best surgical approach for removing underarm lymph nodes in patients with HER2-positive or triple-negative breast cancer who have received chemotherapy before surgery and still have cancer in their lymph nodes. The goal is to understand whether removing more lymph nodes improves outcomes for these patients.
BaselAges Any age - NCT06839001RecruitingPhase 3
Freezing small breast tumors instead of surgery trial
This study tests if freezing a very small early-stage breast tumor (cryoablation) can be as effective as surgery. It may be an option for people whose tumor is small enough and hasn't spread to lymph nodes or elsewhere.
São Paulo, São PauloAges 18 years+ - NCT05916755Recruiting
Testing tumor clues that predict response to immunotherapy
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
BarcelonaAges 18 years+ - NCT07498478RecruitingPhase 2
Tinengotinib and fulvestrant for advanced HR+ HER2- breast cancer
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT06894173Recruiting
Early breast cancer treatment evolution study
This study looks back at treatments given to people with triple-negative or HER2-positive early breast cancer between 2016 and 2021. It aims to understand how treatment approaches have changed over time.
Aviano, PNAges 18 years+ - NCT07242118Recruiting
Radiation therapy for older women with breast cancer
This trial tests a precise, high-dose radiation treatment (called SABR) for older women with early-stage breast cancer who choose not to have surgery. It aims to control the tumor with fewer side effects and may be an option if you have a small, ER+, HER2- tumor that hasn't spread to lymph nodes.
Kansas City, KansasAges 65 years+
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er+ breast cancer?
- Yes. Clin2 currently lists 554 recruiting er+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.